AstraZeneca, Amgen asthma drug tezepelumab secures FDA breakthrough designation
September 9, 2018 No Comment
UK biopharma company AstraZeneca and Amgen have secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for their asthma drug tezepelumab. The FDA breakthrough therapy designation for tezepelumab is for the treatment of patients with severe asthma, without an eosinophilic phenotype, who are administered inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids […]
Continue reading …
Update on Imfinzi EMA approval : The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the approval of AstraZeneca lung cancer drug Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). The committee has recommended Imfinzi EMA approval of […]
Continue reading …
Acalabrutinib FDA approval : AstraZeneca has secured an early approval for its blood cancer drug Calquence (acalabrutinib) for the treatment of mantle cell lymphoma in adult patients who were subjected to a minimum of one prior therapy for the rare type of blood cancer. According to the National Cancer Institute at the National Institutes of […]
Continue reading …AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation
October 15, 2017 No Comment
Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]
Continue reading …
Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]
Continue reading …
AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]
Continue reading …
Business News Today
- TASI acquires German inspection systems manufacturer Cassel Messtechnik
- ALX Oncology raises $105m to advance clinical development of ALX148
- ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase
- McDermott wins contract for six crude oil storage tanks in Texas
- Badin IV South Block, Pakistan : Petroleum Exploration, Jura Energy begin commercial production
- Google wraps up $2.6bn acquisition of data platform company Looker
- ABG buys majority stake in spirits distribution company Indie Brands
- Arthur J. Gallagher acquires Illinois-based Affiliated Benefit Consultants
- Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
- Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
